Results of BioSante’s 2A/Furin technology in industrial antibody CHO expression system announced

Results of BioSante’s 2A/Furin technology in industrial antibody CHO expression system announced
BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line …

Read more on News-Medical-Net

More Meth Drug Addiction Info: